Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
Benign prostatic hyperplasia (BPH) is a complex and progressive disease common in aging men. While associated with bothersome lower urinary tract symptoms, it may also result in additional serious complications such as refractory hematuria, acute urinary retention, and BPH-related surgery. Medical therapy has been offered as an approach to halt this progression and perhaps reverse the pathophysiology of BPH. While alpha-blockers provide rapid relief in the form of improved flow rate, their effects may not reduce the overall risk of BPH-related complications. 5alpha-reductase inhibitors were therefore introduced to affect the underlying disease process by inhibiting the enzyme which converts testosterone to dihydrotesterone, the primary androgen involved in normal and abnormal prostate growth. Through this inhibition, prostate size is decreased, thereby reducing the risk of acute urinary retention and BPH-related surgery while providing symptom control. These effects are most pronounced in men with enlarged prostates (>25 mL) who are at the greatest risk of disease progression. This article reviews the literature for finasteride used in the treatment of BPH and provides evidence for its efficacy, safety and tolerability, applicability for combination therapy, and considerations of its effects on prostate cancer risk.
Smith
Angela B
AB
University of North Carolina Division of Urologic Surgery, Chapel Hill, NC, USA.
Carson
Culley C
CC
Prostate Cancer Prostatic Dis. 2005;8(3):215-8
15999118
J Urol. 2008 Jun;179(6):2333-8
18423697
BMC Clin Pharmacol. 2006 Oct 07;6:7
17026771
Urol Int. 2008;80(2):177-80
18362489
J Urol. 2009 Apr;181(4):1642-57
19249063
Urology. 1998 Aug;52(2):195-201; discussion 201-2
9697781
Eur Urol. 2001 Apr;39(4):390-9
11306876
Urology. 1995 Nov;46(5):631-7
7495111
J Urol. 1995 Oct;154(4):1466-9
7544845
J Urol. 2006 Jan;175(1):217-20; discussion 220-1
16406915
Cancer Prev Res (Phila). 2008 Aug;1(3):174-81
19138953
Prostate. 1992;21(3):247-54
1279647
J Urol. 2000 Feb;163(2):496-8
10647664
Urology. 2003 Jan;61(1):119-26
12559281
Urology. 1994 Mar;43(3):284-92; discussion 292-4
7510911
J Urol. 1993 Feb;149(2):342-4
7678871
Urology. 1996 Sep;48(3):398-405
8804493
J Urol. 1993 Nov;150(5 Pt 2):1736-9
7692110
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091
18425978
Cancer. 2008 Mar 1;112(5):1058-65
18186497
J Sex Med. 2007 Nov;4(6):1708-12
17655657
Eur Urol. 1998 Sep;34(3):169-75
9732187
BJU Int. 2005 Dec;96(9):1319-22
16287453
Prostate. 1993;22(1):31-7
7678930
Prostate. 1993;22(4):291-9
7684524
Urology. 1998 Feb;51(2):237-40
9495704
Annu Rev Biochem. 1994;63:25-61
7979239
J Natl Cancer Inst. 2007 Jul 4;99(13):1025-35
17596576
J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83
17848673
N Engl J Med. 1992 Oct 22;327(17):1185-91
1383816
N Engl J Med. 2003 Dec 18;349(25):2387-98
14681504
J Clin Invest. 1992 Jan;89(1):293-300
1345916
N Engl J Med. 1998 Feb 26;338(9):557-63
9475762
Prostate. 1997 May 15;31(3):180-2
9167770
Cancer Prev Res (Phila). 2008 Aug;1(3):167-73
19138952
N Engl J Med. 1996 Aug 22;335(8):533-9
8684407
Eur Urol. 2003 Oct;44(4):461-6
14499682
Scand J Urol Nephrol. 2007;41(2):124-31
17454951
Am J Health Syst Pharm. 2003 Aug 1;60(15):1511, 1515
12951749
J Urol. 1995 Nov;154(5):1779-82
7563345
Int J Clin Pract. 2008 Jul;62(7):1076-86
18479366
Urology. 2003 Apr;61(4 Suppl 1):2-7
12657354
J Urol. 1998 Oct;160(4):1358-67
9751354
Urology. 1999 Apr;53(4):690-5
10197842
Trans Am Assoc Genitourin Surg. 1976;68:29-32
71777